Dachaigh › Adenocarcinoma Esophageach › Massachusetts
Sgrùdaidhean clionaigeach Adenocarcinoma Esophageach ann an Massachusetts
Tha 13 sgrùdaidhean airson Adenocarcinoma Esophageach a’ lorg phàirtichean aig làraichean ann an Massachusetts.
Bailtean ann an Massachusetts
Teacsa sgrùdaidh oifigeil (Beurla)
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Boston Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- agus 4 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05677490A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07090499Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT06324357Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
- Massachusetts General Hospital, Boston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07546812Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Beth Israel Deaconess Medical Center, Boston
A’ fastadh
Aoisean 18 gu 89 · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Boston
- Research Site, Burlington
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT07431281A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 27 Lùna 2026 · NCT07544589A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT07182149A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- agus 3 a bharrachd
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT04389632Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Ògmh 2026 · NCT07675967First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 12 Ògmh 2026 · NCT07284186Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- I-Mab Site 1002, Boston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Cèit 2026 · NCT07432295Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Màrt 2026 · NCT04900818Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.